A staggering Rs 17 crore for a single jab! That’s the cost of one Zolgensma injection used for children under two suffering from spinal muscular atrophy (SMA), the.
The high cost of Zolgensma, a one-time gene therapy used to treat spinal muscular atrophy (SMA) in children under two, is to limited patient demand and extensive research and development. Although not approved in India, it can be imported with a doctor s recommendation and government approval. This highly expensive drug, costing Rs 17 crore for a single dose, is being sought for a 15-month-old boy in Karnataka by Chief Minister Siddaramaiah. Zolgensma has been developed by Swiss pharmaceutical company Novartis and aims to address the rare genetic disease SMA, which weakens muscles.